Max Allen Schwarzer

Title: Max Allen Schwarzer: Innovator in Tumor Necrosis Factor Receptor Research

Introduction

Max Allen Schwarzer is a notable inventor based in Los Altos, California. He has made significant contributions to the field of biotechnology, particularly in the development of binding molecules for tumor necrosis factor receptors. With a total of three patents to his name, Schwarzer's work has the potential to impact cancer treatment and therapeutic strategies.

Latest Patents

Schwarzer's latest patents include innovative technologies related to death domain-containing receptor-5 (DR5) binding molecules. The first patent discloses dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules. These molecules are designed to direct apoptosis-mediated killing of TNF receptor-expressing cells. The second patent also focuses on multimeric death domain-containing receptor-5 (DR5) antibodies, providing similar methodologies for targeting TNF receptor-expressing cells.

Career Highlights

Throughout his career, Max Allen Schwarzer has worked with prominent companies in the biotechnology sector. Notably, he has been associated with IgM Biosciences, Inc. and IgM Biosciences A/S. His work in these organizations has allowed him to advance his research and contribute to the development of innovative therapeutic solutions.

Collaborations

Schwarzer has collaborated with esteemed colleagues in his field, including Bruce Alan Keyt and Ramesh Baliga. These partnerships have fostered a collaborative environment that enhances research and innovation.

Conclusion

Max Allen Schwarzer is a distinguished inventor whose work in the field of tumor necrosis factor receptor research is paving the way for new therapeutic approaches. His patents and collaborations reflect his commitment to advancing biotechnology and improving cancer treatment options.